Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  SciClone Pharmaceuticals, Inc.    SCLN

SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets 

SciClone to Restate Results for Certain Periods on China Accounting Errors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 11:05pm CEST
   By Debbie Cai 
 

SciClone Pharmaceuticals Inc. (>> SciClone Pharmaceuticals, Inc.) said it will restate its financial statements for certain periods in 2012 and 2011 due mainly to accounting errors at a Chinese subsidiary.

Shares slid 6.2% to $4.52 after hours Friday. The stock is up 12% so far this year.

Chinese drugmaker NovaMed Pharmaceuticals Inc., which SciClone acquired in April 2011, made accounting errors pertaining to the timing of Pfizer Inc. (>> Pfizer Inc.) product-revenue recognition and the recognition of product-return reserves as to antiplatelet drug Aggrastat.

The company will restate financial statements for the first, second and third quarters of last year, the second and third quarters of 2011, and for the full 2011.

SciClone Chief Executive Friedhelm Blobel said the decision to restate financials, which is expected to increase the company's 2012 revenue and earnings and decrease that of 2011, was made after careful review of available facts.

The company believes the changes will raise its revenue for the first nine months of last year by about $3 million, and increase its profit before income taxes by about $2 million. The changes for the full 2011 will lower revenue by about $1 million and decrease income by less than $1 million.

SciClone also said the goodwill related to the acquisition of NovaMed will be increased by approximately $2 million. The restatements wouldn't impact previously reported cash or cash equivalents balances, the company said.

The company said it plans to amend its 2011 10-K form and other relevant filings as soon as reasonably practicable.

Last November, SciClone said it swung to a third-quarter loss as the company works to address issues across its China organization, some of which might have affected sales of its lead drug Zadaxin.

Write to Debbie Cai at debbie.cai@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SciClone Pharmaceuticals, Inc., Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SCICLONE PHARMACEUTICALS,
03/27 SCICLONE PHARMACEUTICALS : To Present At Needham Healthcare Conference On April ..
03/20 SCICLONE PHARMACEUTICALS : How These Drug Makers Stocks are Faring? -- Orexigen ..
03/06 SCICLONE PHARMACEUTICALS, INC. (NASD : SCLN) Files An 8-K Results of Operations ..
03/06 SCICLONE PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
03/06 SCICLONE PHARMACEUTICALS : posts 4Q profit
03/06 SCICLONE PHARMACEUTICALS : Reports 2016 Financial Results And 2017 Outlook
03/01 SCICLONE PHARMACEUTICALS INC : Amendments to Articles of Inc. or Bylaws; Change ..
02/21 SCICLONE PHARMACEUTICALS : To Report Fourth Quarter And Full Year 2016 Financial..
02/09 SCICLONE PHARMACEUTICALS : Healthcare Stocks Under Scanner -- Aerie Pharma, GW P..
02/09 SCICLONE PHARMACEUTICALS : To Present At BIO CEO & Investor Conference On Februa..
More news
Sector news : Pharmaceuticals - NEC
03/27DJALEXION PHARMACEUTICALS : Names New CEO Following Internal Sales-Practice Probe
03/27DJEU Clears Dow-DuPont Deal With Conditions -- 2nd Update
03/27DJEU Clears Dow-DuPont Deal With Conditions -- Update
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/06 SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q4 2016 Results - Ea..
03/06 SciClone Pharmaceuticals reports Q4 results
02/02 SCICLONE PHARMACEUTICALS : Beyond The Death Of A Sales Process
2016 Adds and drops from the Nasdaq Biotech Index
2016 WEEK IN REVIEW : Week's China Life Science Deals Total $795 Million
Advertisement
Chart SCICLONE PHARMACEUTICALS,
Duration : Period :
SciClone Pharmaceuticals,  Technical Analysis Chart | SCLN | US80862K1043 | 4-Traders
Full-screen chart
Technical analysis trends SCICLONE PHARMACE...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Managers
NameTitle
Friedhelm Blobel President, Chief Executive Officer & Director
Jon Sheldon Saxe Chairman
Wai-Shun Wilson Cheung Chief Financial Officer, Secretary & SVP-Finance
Rick J. Hawkins Independent Director
Gregg Anthony Lapointe Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SCICLONE PHARMACEUTICA..-9.72%502
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results